Preserving vision in Usher syndrome
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This 24-month study tests an experimental medication, NPI-001, to see if it can slow or prevent further vision loss in people with Usher syndrome. Usher syndrome affects hearing and vision, and this trial focuses on protecting the light-sensing cells in the retina.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Usher syndrome.
- Your vision loss is not too advanced—specific tests at the start must show enough remaining retinal function.
- You are not currently taking N-acetylcysteine supplements (and can stop them for the trial).
- You have no other major eye diseases (like glaucoma or severe cataracts) that would interfere.
- You are generally healthy, without serious liver, kidney, or blood conditions.
- You are willing to use contraception or abstain from intercourse during the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This study checks the long-term safety of a medicine called ultevursen for people with retinitis pigmentosa caused by changes in a specific gene. It is for people who have already finished the earlier LUNA study and might continue treatment or just be followed for observation.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.